

Prequalified Medicinal Products



Reference Number: TB299

Date of prequalification: 11 July 2016 **Basis of listing:** Prequalified by WHO

Status: Active INN: Linezolid

Therapeutic area: Tuberculosis

Dosage form & strength: Tablet, Film-coated 600mg

Storage condition: Do not store above 30°C

Shelf life (months): 36

Packaging: Blister Alu/Alu 10x10; Bottle HDPE 20x1, 100x1

Applicant:

Hetero Labs Ltd, Unit 5, Survey No 439, 440, 441 & 458 TSIIC Formulation SEZ, Polepally Village, Jadcherla (M), Mahaboob Nagar District, Telangana, 509 301, India

FPP Manufacturing Site:

Hetero Labs Ltd, Unit 5, Survey No 439, 440, 441 & 458 TSIIC Formulation SEZ, Polepally Village, Jadcherla (M), Mahaboob Nagar District, Telangana, 509 301, India

FPP WHO Public Inspection Reports:

Hetero Labs, Unit V - (15 - 18 June 2015),

Telangana State, India

API Manufacturing Site:

(Linezolid) Symed Labs Ltd, Survey No 353, Domadugu (Village), Jinnaram (Mandal), Medak (Dist), Telangana, 502 313, India

API WHO Public Inspection Reports:

Symed Labs Ltd - Unit I - Desk Review - (26 November 2018),

Telangana, India

WHO Public Assessment Reports

- Part 1 Abstract
- Part 2 All accepted presentations (including photo)
- Part 3 WHO-PQ recommended patient information leaflet*
- Part 4 WHO-PQ recommended summary of product characteristics*
- Part 5 Label
- Part 6 Discussion (status at the time of prequalification)
- Part 7 Steps before Prequalification
- Part 8 Steps following Prequalification (from 01 March 2014, only changes to the published information are included)
- * This summary of product characteristics/patient information leaflet focus on uses of the medicine covered by WHO Prequalification Team - Medicines. The recommendations for use are based on WHO guidelines and on information from stringent regulatory authorities (term to be revised). The medicine may be authorised for additional or different uses by national medicines regulatory authorities.

https://www.facebook.com/WHO

© 2021 WHO Prequalification